Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

Hims & Hers Health Inc.'s stock was headed for a record session of losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...

BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. | BrightGene ...

Shares in two companies slide as Danish drugmaker accuses US telehealth group of deceptively marketing replica treatments ...

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.

The combination offers a potential solution to one of the key problems that’s emerged with popular obesity shots.

The report spotlights China’s rapid biopharma advancement, alongside a GLP-1 surge, caution surrounding M&A, and a rise in ...

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...